Cubist Systematic Strategies LLC Sells 37,971 Shares of Immunocore Holdings PLC Sponsored ADR $IMCR

Key Points

• Cubist Systematic Strategies LLC reduced its stake in Immunocore Holdings PLC by 35.6%, selling 37,971 shares and retaining 68,629 shares valued at approximately $2,036,000.
• Immunocore's stock experienced a 5.5% increase, with a current share price of $37.20, while its quarterly earnings surpassed analyst expectations with a revenue of $130.65 million.
• The company's stock ratings are mixed, with seven analysts giving a "buy" rating and an average price target of $56.89 according to MarketBeat.

Cubist Systematic Strategies LLC reduced its stake in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Free Report) by 35.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 68,629 shares of the company's stock after selling 37,971 shares during the quarter. Cubist Systematic Strategies LLC owned approximately 0.14% of Immunocore worth $2,036,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in Immunocore in the 4th quarter worth approximately $25,000. Oppenheimer Asset Management Inc. acquired a new stake in Immunocore in the 1st quarter worth approximately $225,000. Tema Etfs LLC acquired a new stake in Immunocore in the 4th quarter worth approximately $330,000. GAMMA Investing LLC increased its position in Immunocore by 3,318.1% in the 1st quarter. GAMMA Investing LLC now owns 19,107 shares of the company's stock worth $5,670,000 after buying an additional 18,548 shares during the period. Finally, Persistent Asset Partners Ltd bought a new position in Immunocore in the 1st quarter worth approximately $663,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IMCR has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft initiated coverage on Immunocore in a research report on Tuesday, May 27th. They issued a "buy" rating and a $65.00 price target on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $100.00 price target on shares of Immunocore in a research report on Monday, June 2nd. Wall Street Zen downgraded Immunocore from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Zacks Research downgraded Immunocore from a "strong-buy" rating to a "hold" rating in a research report on Thursday, September 4th. Finally, Jefferies Financial Group initiated coverage on Immunocore in a research report on Monday, August 25th. They issued a "buy" rating and a $48.00 price target on the stock. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Immunocore has a consensus rating of "Hold" and an average price target of $56.89.

Immunocore Stock Performance

Shares of IMCR traded down $1.33 on Friday, reaching $35.24. 184,758 shares of the stock traded hands, compared to its average volume of 272,261. The stock's 50-day moving average price is $33.99 and its 200-day moving average price is $31.77. Immunocore Holdings PLC Sponsored ADR has a 12 month low of $23.15 and a 12 month high of $39.33. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -88.10 and a beta of 0.77. The company has a debt-to-equity ratio of 1.01, a current ratio of 5.89 and a quick ratio of 5.86.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. Immunocore had a negative return on equity of 5.40% and a negative net margin of 5.70%.The firm had revenue of $130.65 million for the quarter, compared to analysts' expectations of $122.96 million. During the same period in the prior year, the business posted ($0.23) earnings per share. The business's revenue was up 30.0% compared to the same quarter last year. Equities analysts forecast that Immunocore Holdings PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.